Open AccessTHE PERSONALIZED APPROACH TO ANTIHYPERTENSIVE THERAPY DURING PREGNANCY IN TERMS OF CLINICAL PHARMACOGENETICS
Author(s) -
И.В. Игнатко,
Игнатко Ирина Владимировна,
Л. А. Стрижаков,
Стрижаков Леонид Александрович,
Violetta Florova,
Флорова Виолетта Сергеевна,
A.L. Martirosova,
Мартиросова Алина Лорисовна
Publication year - 2018
Publication title -
vestnik rossijskoj akademii medicinskih nauk
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.122
H-Index - 15
eISSN - 2414-3545
pISSN - 0869-6047
DOI - 10.15690/vramn954
Subject(s) - pharmacogenetics , pregnancy , pharmacotherapy , medicine , personalized medicine , drug , intensive care medicine , bioinformatics , pharmacology , fetus , clinical pharmacology , genotype , biology , genetics , gene
The right drug at the right dose administered to a patient in time is the goal which all medical specialists aim at when prescribing medicines to patients. Pregnancy is a condition when the principle of personalized pharmacotherapy is especially relevant. Due to the developing fetus and the occurring changes in the maternal organism, the selection of drug therapy during pregnancy is especially difficult for a clinician. This issue is tightly intertwined with clinical pharmacogenetics since the genetic code of a woman that determines the activity of the liver cytochrome, the fetus-placental barrier, and renal clearance contributes to the peculiarities of the drug metabolism during pregnancy. Additional data provides the opportunities to form therapeutic models and to determine the ways of personifying pharmacotherapy in pregnancy. The purpose of this review is to summarize the available data on the pharmacogenetics of antihypertensive drugs used during pregnancy.